Novo Nordisk Frontier 4

News

Novo Nordisk ousts CEO

Novo Nordisk CEO steps down as Wegovy maker faces increased competition

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

Reuters on MSN · 1d

Talks to replace Novo Nordisk CEO lasted several weeks, board chair says

Discussions between Novo Nordisk and the Novo Nordisk Foundation that controls the company regarding a CEO change have been ongoing for the past few weeks, the company's board Chair Helge Lund told Reuters on Friday.

NBC4 Washington · 1d

Novo Nordisk CEO to step down as Wegovy maker faces growing competition

The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post “for a period to support a smooth transition to new leadership.”

Zacks Investment Research on MSN2d

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. Following the ...

19hon MSN

Novo Nordisk, U.S. biotech company team up to create obesity pills

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Yahoo Finance24d

Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO ... By comparison, Ozempic led to mean A1C level reductions of 1.4% to 1.6% after 30 weeks, while also decreasing body weight by an ...

Morningstar9d

Novo Nordisk shares are rising after the company cut its outlook. It's been that kind of year.

Analysts polled by Visible Alpha expected a profit of 27.61 billion kroner on revenue of 78.4 billion kroner. Novo Nordisk says it's now cutting its annual outlook - seeing sales growth ...

Novo Nordisk rode Ozempic’s success to becoming Europe’s top company. Now it’s faltering and its CEO is out.

Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results